Grit Biotechnology

This early-phase study tested an experimental treatment called GT101 for people with advanced solid tumors that had spread or returned. The approach involved collecting the patient's own immune cells from the tumor, growing them in a lab, and giving them back along with chemother…

This early-stage trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy an…

This early-phase study tested an experimental therapy called GT201, made from a patient's own immune cells, for advanced gynecological tumors. Only one person took part before the study was stopped. The goal was to see if the treatment could shrink tumors, but it is not expected …

This early-phase study tested a personalized therapy called GT201 for people with advanced solid tumors that have spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy a…

This early study tested a new treatment called GT201 for people with advanced gynecological tumors, including cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was very small with only 4 participants a…

This trial tested a treatment that uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced solid tumors. The goal was to see if it was safe and tolerable. Only 2 people took part before the study was stopped early.

This study tested a treatment called GT201, which uses immune cells taken from a patient's own tumor to attack cancer. It was designed for adults with advanced lung cancer who had already tried other treatments. The study was stopped early after enrolling only 2 people, so result…

This study tested a new treatment for advanced non-small cell lung cancer using a patient's own immune cells (TILs) combined with an immunotherapy drug. The goal was to see if the combination was safe and tolerable. However, the trial was terminated early and only enrolled 2 peop…

This early-phase study tested a personalized treatment called GTE-001, made from a patient's own tumor-fighting immune cells. It aimed to see if these cells could shrink tumors in adults with advanced lung adenocarcinoma that had worsened after chemotherapy. Only 2 people enrolle…